The University of Chicago Header Logo

Connection

Mark W. Lingen to Radiotherapy Dosage

Back to Details
This is a "connection" page, showing publications Mark W. Lingen has written about Radiotherapy Dosage.
Mark W. Lingen
Connection Strength
0.032
Radiotherapy Dosage
  1. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.